{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:40:27Z","timestamp":1780468827445,"version":"3.54.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T00:00:00Z","timestamp":1706227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Tolvaptan, a selective vasopressin V<jats:sub>2<\/jats:sub>-receptor antagonist, can elicit a diuretic effect without significant electrolyte loss. The aims were to evaluate multiple-dose pharmacokinetics, pharmacodynamics and safety of daily administration of 15\u00a0mg tolvaptan in Chinese adult patients with confirmed Child-Pugh Class B cirrhosis accompanied by ascites.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This was an open-label, single-center, single- and multiple-dose study. All patients received a daily 15\u00a0mg dose of tolvaptan for 7 consecutive days. The plasma concentrations of tolvaptan and its two metabolites (DM-4103, DM-4107) were measured using high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS\/MS). In addition, various pharmacokinetics parameters were calculated. The pharmacodynamic outcomes evaluated changes in serum sodium and potassium concentrations, daily urine volume, daily water consumption, fluid balance and body weight. Safety profiles, including the incidence of treatment-emergent adverse events (TEAEs), were carefully recorded.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Eleven patients with Child-Pugh B cirrhosis were eventually enrolled in the study. Plasma concentrations of tolvaptan and DM-4107 reached steady-states after 7 days of consecutive oral administration. No accumulation of tolvaptan or DM-4107 was found, but DM-4103 accumulated 18.2-fold after multiple-dosing. The daily urine volume and daily water consumption were statistically significantly increased after administration of tolvaptan from Day 1 to Day 7 (all <jats:italic>p<\/jats:italic> &amp;lt; 0.05), accompanied by an increased serum sodium concentration. Of 11 patients, 9 (81.8%) reported 20 TEAEs, with the majority being mild to moderate in severity. The most commonly occurring TEAEs were thirst (45.5%), pollakiuria (36.4%) and dry mouth (27.3%).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Tolvaptan at a daily dose of 15\u00a0mg had a diuretic effect but did not increase serum sodium excretion or lead to tolvaptan accumulation. It is therefore can be safely used for short-term treatment of Chinese adult patients with confirmed Child-Pugh B cirrhosis.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold><jats:ext-link>https:\/\/clinicaltrials.gov\/search?term=NCT01359462<\/jats:ext-link>, identifier NCT01359462.<\/jats:p>","DOI":"10.3389\/fphar.2024.1324299","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T04:48:40Z","timestamp":1706244520000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics, pharmacodynamics and safety of 15\u00a0mg-tolvaptan administered orally for 7 consecutive days to Chinese patients with child-Pugh B cirrhosis"],"prefix":"10.3389","volume":"15","author":[{"given":"Hongzhong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minde","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3760\/cma.j.cn501113-20230719-00011","article-title":"Guidelines on the management of ascites in cirrhosis (2023 version)","volume":"31","year":"2023","journal-title":"Chin. J. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2125.2011.04029.x","article-title":"Tolvaptan","volume":"73","author":"Dubois","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B3","first-page":"288","article-title":"Effects of the V(2)-receptor antagonist opc-41061 and the loop diuretic furosemide alone and in combination in rats","volume":"292","author":"Hirano","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1007\/s10557-011-6299-3","article-title":"Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide avp V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers","volume":"25","author":"Kim","year":"2011","journal-title":"Cardiovasc Drugs Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/hepr.12099","article-title":"Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: a randomized, double-blind, placebo-controlled trial","volume":"44","author":"Okita","year":"2014","journal-title":"Hepatol. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00535-010-0240-6","article-title":"A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis","volume":"45","author":"Okita","year":"2010","journal-title":"J. Gastroenterol."},{"key":"B7","unstructured":"Otsuka America pharmaceutical, Inc. Tolvaptan2022"},{"key":"B8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/hepr.12098","article-title":"Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"44","author":"Sakaida","year":"2014","journal-title":"Hepatol. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00535-020-01691-x","article-title":"Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (start study)","volume":"55","author":"Sakaida","year":"2020","journal-title":"J. Gastroenterol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1177\/0300060513480089","article-title":"Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema","volume":"41","author":"Sakaida","year":"2013","journal-title":"J. Int. Med. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1177\/030006051204000637","article-title":"The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase iii study","volume":"40","author":"Sakaida","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2125.2011.04114.x","article-title":"Effects of Cyp3a4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide avp antagonist in healthy subjects","volume":"73","author":"Shoaf","year":"","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/cts.13017","article-title":"Regulatory guidelines do not accurately predict tolvaptan and metabolite interactions at bcrp, Oatp1b1, and Oat3 transporters","volume":"14","author":"Shoaf","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00228-012-1295-5","article-title":"Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy caucasian and Japanese male subjects","volume":"68","author":"Shoaf","year":"","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1177\/0091270007307877","article-title":"Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide avp antagonist, during ascending single-dose studies in healthy subjects","volume":"47","author":"Shoaf","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12876-020-01536-0","article-title":"Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase iii clinical trial","volume":"20","author":"Tang","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/bdd.1849","article-title":"Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis","volume":"34","author":"Van Wart","year":"2013","journal-title":"Biopharm. Drug Dispos."},{"key":"B20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/1751-2980.12583","article-title":"Tolvaptan in Chinese cirrhotic patients with ascites: a randomized, placebo-controlled phase 2 trial","volume":"19","author":"Wang","year":"2018","journal-title":"J. Dig. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/FJC.0b013e318241e89c","article-title":"Pharmacokinetics and pharmacodynamics of oral tolvaptan administered in 15- to 60-Mg single doses to healthy Korean men","volume":"59","author":"Yi","year":"2012","journal-title":"J. Cardiovasc Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1324299\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T04:48:44Z","timestamp":1706244524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1324299\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":22,"alternative-id":["10.3389\/fphar.2024.1324299"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1324299","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]},"article-number":"1324299"}}